Similar articles

• Clinical feasibility of islet transplantation.

  Scharp DW. Scharp DW. Transplant Proc. 1984 Jun;16(3):820-5. Transplant Proc. 1984. PMID: 6328706 No abstract available.
• Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice.

  Banuelos SJ, Shultz LD, Greiner DL, Burzenski LM, Gott B, Lyons BL, Rossini AA, Appel MC. Banuelos SJ, et al. Clin Immunol. 2004 Sep;112(3):273-83. doi: 10.1016/j.clim.2004.04.006. Clin Immunol. 2004. PMID: 15308121
• Manipulation of pancreatic islet cells in allotransplantation.

  Tze WJ, Tai J. Tze WJ, et al. Transplant Proc. 1982 Dec;14(4):714-23. Transplant Proc. 1982. PMID: 6820204 Review. No abstract available.
• Experimental and clinical therapy of diabetes by transplantation.

  Jonasson O, Reynolds WA, Snyder G, Hoversten G. Jonasson O, et al. Transplant Proc. 1977 Mar;9(1):223-32. Transplant Proc. 1977. PMID: 405769 Review.
• Physiologic and immunologic status of long-functioning transplanted pancreatic islets in rats.

  Reckard CR, Ziegler MM, Naji A, Galbut D, Barker CF. Reckard CR, et al. Surg Forum. 1974;25(0):374-6. Surg Forum. 1974. PMID: 4216091 No abstract available.